Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units

Background: The results of several studies have suggested that infections and sepsis, either bacterial or viral, might be associated with elevated plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels. Since there are no data on PCSK9 levels and antibiotic resistance or the severity of disease in patients with bacterial infections in intensive care units, the aim of this study was to investigate whether any such associations exist. Methods: 100 patients (46 males, mean age 67.12 ± 1.34 years) with bacterial infections who were staying in an intensive care unit (ICU) longer than 48 h but less than 7 days and who were not receiving corticosteroids were analyzed. Their serum levels of albumin, C-reactive protein, glucose, lactate, blood urea nitrogen, prothrombin (international normalized ratio), total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, PCSK9, and procalcitonin were measured. The severity of the patients’ condition was assessed by using the Glasgow Coma Scale (GCS), the Sequential Organ Failure Assessment (SOFA), and the Acute Physiology and Chronic Health Evaluation II (APACHE II) scales. Results: Using a hierarchical regression modeling approach, no significant association was found between PCSK9 levels and either the severity of disease (APACHE II, SOFA, and GCS) indices or resistance to antibiotics. Conclusion: The results suggest that there is no association between PCSK9 levels and resistance to antibiotics or the condition of patients hospitalized in intensive care units.

[1]  Wei-Qi Wei,et al.  A Genetic Approach to the Association Between PCSK9 and Sepsis , 2019, JAMA network open.

[2]  C. Fjell,et al.  Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients , 2019, Scientific Reports.

[3]  Z. Ortutay,et al.  Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality , 2019, Journal of internal medicine.

[4]  Henry E. Wang,et al.  PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort , 2019, PloS one.

[5]  G. Francis,et al.  Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors , 2018, EBioMedicine.

[6]  A. Prat,et al.  Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor , 2018, Scientific Reports.

[7]  A. Sahebkar,et al.  PCSK9 and infection: A potentially useful or dangerous association? , 2018, Journal of cellular physiology.

[8]  Ž. Reiner PCSK9 inhibitors in clinical practice: Expectations and reality. , 2018, Atherosclerosis.

[9]  F. Fallarino,et al.  PCSK9 at the crossroad of cholesterol metabolism and immune function during infections , 2017, Journal of cellular physiology.

[10]  D. Francisci,et al.  Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism , 2017, Journal of cellular and molecular medicine.

[11]  I. Pećin,et al.  Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors , 2017, European journal of preventive cardiology.

[12]  J. Gromada,et al.  Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice[S] , 2017, Journal of Lipid Research.

[13]  M. Banach,et al.  PCSK9 and diabetes: is there a link? , 2017, Drug discovery today.

[14]  John D. Davis,et al.  Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). , 2017, The American journal of cardiology.

[15]  M. Banach,et al.  PCSK9 inhibitors in sepsis: a new potential indication? , 2017, Expert opinion on investigational drugs.

[16]  A. Prat,et al.  Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis , 2016, Shock.

[17]  S. Ishibashi,et al.  Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report. , 2016, Journal of clinical lipidology.

[18]  P. Ganz,et al.  HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox” , 2016, Journal of the American Heart Association.

[19]  C. Fjell,et al.  Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis , 2016, Journal of Innate Immunity.

[20]  G. Francis,et al.  The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. , 2015, American journal of respiratory and critical care medicine.

[21]  Ž. Reiner Management of patients with familial hypercholesterolaemia , 2015, Nature Reviews Cardiology.

[22]  J. Mehta,et al.  Cross-talk between LOX-1 and PCSK9 in vascular tissues. , 2015, Cardiovascular research.

[23]  Ž. Reiner PCSK9 inhibitors – past, present and future , 2015, Expert opinion on drug metabolism & toxicology.

[24]  J. Mehta,et al.  Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. , 2015, Antioxidants & redox signaling.

[25]  M. Reilly,et al.  PCSK9 is a critical regulator of the innate immune response and septic shock outcome , 2014, Science Translational Medicine.

[26]  A. Siddiqui,et al.  Hepatitis C Virus Stimulates Low-Density Lipoprotein Receptor Expression To Facilitate Viral Propagation , 2013, Journal of Virology.

[27]  G. Watts,et al.  New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect? , 2013, Cardiovascular Drugs and Therapy.

[28]  K. Asehnoune,et al.  Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. , 2013, The Journal of clinical endocrinology and metabolism.

[29]  M. Chrétien My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. , 2012, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[30]  K. Azzam,et al.  Crosstalk between reverse cholesterol transport and innate immunity , 2012, Trends in Endocrinology & Metabolism.

[31]  P. Ganz,et al.  HIV and Hepatitis C – Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 ( PCSK 9 ) : An Apparent “ PCSK 9 – Lipid Paradox ” , 2016 .